article thumbnail

Maui Derm News: Kids With Severe AD Catch Up on Growth With Dupilumab

The Dermatology Digest

Dupilumab (Dupixent, Sanofi & Regeneron) may boost height in kids with severe atopic dermatitis (AD), according to a late-breaking abstract presented at Maui Derm Hawaii 2025. Cyr, PhD, Senior Director of Medical Affairs at Regeneron Pharmaceuticals, received the best poster Akamai Award at the meeting.

article thumbnail

JNJ Continues to Grow AD Pipeline With New Licensing Agreement

The Dermatology Digest

Johnson & Johnson has entered into an exclusive licensing agreement for the global development, manufacturing and commercialization of a STAT6 program for autoimmune and allergic diseases, including atopic dermatitis (AD), from Kaken Pharmaceutical.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Derm-Biome Adds Dr. Jerry Tan to Its Scientific Advisory Board

The Dermatology Digest

Jerry Tan, MD, is joining Derm-Biome Pharmaceuticals, Inc.’s s Scientific Advisory Board.

article thumbnail

Oh, What a Year! The Skin of Color Society Reflects on Its Dynamic 2024

The Dermatology Digest

Alexis and Kwatra “Seborrheic Dermatitis in Skin of Color” with Drs. The 20th Annual SOCS Scientific Symposium was generously supported by the following sponsors: AbbVie, Johnson & Johnson, Sanofi and Regeneron Pharmaceuticals, Inc. Adotama and Luke “A Fresh Look at Aging” with Drs.

Webinar 78
article thumbnail

Weighing Risks Vs. Benefits of Systemic AD Treatments

The Dermatology Digest

Shared-decision making focused on weighing risks versus benefits is key when choosing the most appropriate systemic atopic dermatitis (AD) treatment for a patient, according to new research presented at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Washington, DC.

article thumbnail

Patent Dispute Update: Incyte Blocks U.S. Launch of Sun Pharma’s Deuruxolitinib (Leqselvi) for Alopecia Areata

The Dermatology Digest

Incyte filed a lawsuit to try to block the launch of deuruxolitinib, claiming that it infringed on a patent on the use of ruxolitinib (Opzelura), which is approved for atopic dermatitis and vitiligo. Sun Pharma acquired deuruxolitinib when it purchased Concert Pharmaceuticals in March 2023 and received the U.S,

article thumbnail

Oh, The Places Dermatology Will Go in 2024!

The Dermatology Digest

Dupilumab (Dupixent, Regeneron Pharmaceuticals, Inc., New systemic agents and even new concepts in the prevention of atopic dermatitis and the microbiome seem just around the corner too, Dr. Lio says. “We Food and Drug Administration (FDA) recently OKed a label update for dupilumab (Dupixent, Regeneron Pharmaceuticals, Inc.,